Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone

Zaineb A F Albayati,Manjula Sunkara,Suzannah M Schmidt-Malan,Melissa J Karau,Andrew J Morris,James M Steckelberg,Robin Patel,Philip J Breen,Mark S Smeltzer,K Grant Taylor,Kevyn E Merten,William M Pierce,Peter A Crooks
DOI: https://doi.org/10.1128/AAC.01609-15
2015-12-14
Abstract:We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
What problem does this paper attempt to address?